MCID: CHR064
MIFTS: 36

Chronic Monocytic Leukemia

Categories: Blood diseases, Cancer diseases

Aliases & Classifications for Chronic Monocytic Leukemia

MalaCards integrated aliases for Chronic Monocytic Leukemia:

Name: Chronic Monocytic Leukemia 12 15
Leukemia, Monocytic, Chronic 71
Leukemia, Myeloid 44

Classifications:



External Ids:

Disease Ontology 12 DOID:8593
ICD9CM 34 206.1
MeSH 44 D007951
NCIt 50 C34774
SNOMED-CT 67 46236001
ICD10 32 C93.1
UMLS 71 C0023466

Summaries for Chronic Monocytic Leukemia

MalaCards based summary : Chronic Monocytic Leukemia, also known as leukemia, monocytic, chronic, is related to leukemia, acute myeloid and atypical chronic myeloid leukemia. An important gene associated with Chronic Monocytic Leukemia is ITGAD (Integrin Subunit Alpha D), and among its related pathways/superpathways is Phagocytosis of Microbes. The drugs Micafungin and Lenalidomide have been mentioned in the context of this disorder. Affiliated tissues include myeloid, t cells and bone, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Chronic Monocytic Leukemia

Graphical network of the top 20 diseases related to Chronic Monocytic Leukemia:



Diseases related to Chronic Monocytic Leukemia

Symptoms & Phenotypes for Chronic Monocytic Leukemia

GenomeRNAi Phenotypes related to Chronic Monocytic Leukemia according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00240-S-1 9.17 ITGAD
2 Decreased viability GR00381-A-1 9.17 ITGAD LGALS1
3 Decreased viability GR00381-A-2 9.17 LGALS1
4 Decreased viability GR00381-A-3 9.17 ITGAD LGALS1
5 Decreased viability GR00386-A-1 9.17 LGALS1

Drugs & Therapeutics for Chronic Monocytic Leukemia

Drugs for Chronic Monocytic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 514)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Micafungin Approved, Investigational Phase 4 235114-32-6 3081921 477468
2
Lenalidomide Approved Phase 4 191732-72-6 216326
3
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
4
tannic acid Approved Phase 4 1401-55-4
5 Aclacinomycins Phase 4
6 Angiogenesis Inhibitors Phase 4
7
Iron Approved Phase 2, Phase 3 7439-89-6 23925 29936
8
Lorazepam Approved Phase 3 846-49-1 3958
9
Adenosine Approved, Investigational Phase 3 58-61-7 60961
10
Peginterferon alfa-2a Approved, Investigational Phase 3 198153-51-4 5360545
11
Caspofungin Approved Phase 3 162808-62-0, 179463-17-3 468682 2826718
12
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
13 Orange Approved Phase 2, Phase 3
14
Ofloxacin Approved Phase 3 82419-36-1 4583
15
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
16
Morphine Approved, Investigational Phase 3 57-27-2 5288826
17
Carvedilol Approved, Investigational Phase 3 72956-09-3 2585
18
Enalaprilat Approved Phase 3 76420-72-9 6917719
19
Enalapril Approved, Vet_approved Phase 3 75847-73-3 5362032 40466924
20
Tacrolimus Approved, Investigational Phase 3 104987-11-3 445643 439492 6473866
21
Panobinostat Approved, Investigational Phase 3 404950-80-7 6918837
22
leucovorin Approved Phase 3 58-05-9 6006
23
Cladribine Approved, Investigational Phase 3 4291-63-8 20279
24
Thioguanine Approved Phase 3 154-42-7 2723601
25
Mercaptopurine Approved Phase 3 50-44-2 667490
26
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
27
Iodine Approved, Investigational Phase 3 7553-56-2 807
28
Amsacrine Approved, Investigational Phase 3 51264-14-3 2179
29
Atorvastatin Approved Phase 3 134523-00-5 60823
30
Captopril Approved Phase 3 62571-86-2 44093
31
Etoposide Approved Phase 3 33419-42-0 36462
32
Coal tar Approved Phase 2, Phase 3 8007-45-2
33
Venetoclax Approved, Investigational Phase 3 1257044-40-8 49846579
34
Guaifenesin Approved, Investigational, Vet_approved Phase 2, Phase 3 93-14-1 3516
35
Heparin Approved, Investigational Phase 3 9005-49-6 772 9812414
36
Ponatinib Approved, Investigational Phase 3 943319-70-8 24826799
37
Mycophenolic acid Approved Phase 3 24280-93-1 446541
38
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
39 Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
40
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
41
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
42
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
43
Hydroxyurea Approved Phase 2, Phase 3 127-07-1 3657
44
Voriconazole Approved Phase 3 137234-62-9 71616
45
Arsenic trioxide Approved, Investigational Phase 3 1327-53-3 518740
46
Peginterferon alfa-2b Approved Phase 2, Phase 3 215647-85-1, 99210-65-8
47
Glycine Approved, Nutraceutical, Vet_approved Phase 3 56-40-6 750
48
Aspartic acid Approved, Nutraceutical Phase 3 56-84-8 5960
49
Asparagine Approved, Investigational, Nutraceutical Phase 3 70-47-3 6267
50 Amonafide Investigational Phase 3 69408-81-7

Interventional clinical trials:

(show top 50) (show all 2493)
# Name Status NCT ID Phase Drugs
1 A Randomized Comparison of Fludarabine in Combination With Cytarabine Versus High -Dose Cytarabine in Post-remission Therapy for AML1-ETO Acute Myeloid Leukemia Unknown status NCT02024308 Phase 4 Fludarabine;Cytarabine
2 Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell Transplantation Unknown status NCT01806116 Phase 4 decitabine
3 A Phase IV, Randomized Study to Evaluate the Safety and Efficacy of Idarubicin at Different Dosages Combined With Cytarabine as Induction Therapy for Newly Diagnosed Acute Myeloid Leukaemia Unknown status NCT02277847 Phase 4 Idarubicin(8mg/m2) and cytosine arabinoside;Idarubicin(10mg/m2), cytosine arabinoside
4 Multicenter Randomised Clinical Trial in Acute Myeloid Leukemia Treatment Based on Three Anthracyclines, Comparing Two Types of Consolidation With Different ARA-C Doses Followed by One Year Maintenance Unknown status NCT01587430 Phase 4 high dose ARA-C;standard dose ARA-C
5 Fludarabine and Cytarabine Versus High-dose Cytarabine in Consolidation Treatment of Core-bing Factor Acute Myeloid Leukemia: A Prospective, Multicenter, Randomized Study Unknown status NCT02926586 Phase 4 Fludarabine;Cytarabine
6 Early Tapering of Immunosuppressive Agents After Allogeneic Hematopoietic Stem Cell Transplantation Can Improve the Survival of Patients With Advanced Acute Myeloid Leukemia. Unknown status NCT03150134 Phase 4 Cyclosporine;routine reduction of immunosuppressive drugs(cyclosporine)
7 Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia Unknown status NCT02317159 Phase 4 Imatinib
8 Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia Unknown status NCT03216070 Phase 4 Dasatinib 50 MG
9 ASSESSMENT OF GH-IGF1 AXIS AND TO STUDY RESPONSE TO GH THERAPY IN CHILDREN WITH CML IN REMISSION HAVING GH DEFICIENCY Unknown status NCT01901666 Phase 4 Growth Hormone
10 A Phase IV Study of Corticosteroids As Prophylaxis for Infusion-Related Adverse Events to Mylotarg® in Patients With Acute Myelogenous Leukemia (AML) Completed NCT00304447 Phase 4 Mylotarg
11 Open-Label, Multicenter, Effects of Remission Maintenance Therapy With Ceplene® , Given in Conjunction With Low-Dose Interleukin-2, on Immune Response and Minimal Residual Disease in Adult Patients With AML in First Complete Remission Completed NCT01347996 Phase 4 histamine dihydrochloride and IL-2
12 A Randomized Open-Label Trial of Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome Completed NCT01200355 Phase 4 micafungin;posaconazole
13 Incidence of Invasive Fungal Disease in Patients Receiving Immunosuppressive Therapy, Intensive Chemotherapy or Reduced Intensity Haematopoietic Stem Cell Transplantation on Posaconazole Prophylaxis Completed NCT02875743 Phase 4 Posaconazole
14 PETHEMA-LAM99:Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years Completed NCT00464217 Phase 4 ARA-C;Idarubicin;Leucomax
15 AML96 - Risk-Adapted and Randomized Postremission-Therapy for Adult Acute Myeloid Leukemia Patients. A Cooperative AML-Study of the German SHG-Study Group. Completed NCT00180115 Phase 4 Cytarabine Dosage
16 AML2003 - Randomized Comparison Between Standard-Therapy and Intensified Therapy for Adult Acute Myeloid Leukemia Patients <= 60 Years. A Prospective, Randomized, Multi-center Therapy-Optimizing-Study. Completed NCT00180102 Phase 4 Cytarabine vs. Cytarabine+Amsacrine+Mitoxantrone
17 Incidence of Respiratory Viral Infections During AML Induction and Consolidation Chemotherapy Completed NCT01819792 Phase 4
18 Randomised Multicentre Phase IV Study to Compare Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec® in Combination With Interferon Alpha at Low Doses in the Treatment of Newly-Diagnosed Chronic-Phase Chronic Myeloid Leukaemia Completed NCT00390897 Phase 4 Glivec;Interferon
19 A Phase 4 Study of the Pharmacokinetics of Oral Posaconazole (SCH 56592) Among Patients With Compromised Gastrointestinal Function and at High Risk for Invasive Fungal Infection Completed NCT00686543 Phase 4 Posaconazole
20 A Multi-center, Open-label, Exploratory Study of Bcr-Abl Kinetics in Adult Patients on Nilotinib With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) and a Suboptimal Molecular Response to Imatinib Completed NCT00644878 Phase 4 Nilotinib
21 A Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib Completed NCT01660906 Phase 4 Dasatinib
22 FLAT: Fludarabine, Cytarabine and Topotecan in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia Completed NCT00488709 Phase 4 Topotecan;Fludarabine;Cytarabine
23 FLAG-IDA Chemotherapy Induction Follow by Intensive Chemotherapy Postremission +/- Autologous Hemopoietic Stem Cell Transplantation or Bone Marrow Transplantation in Patients With High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia. Completed NCT00487448 Phase 4 Fludarabine;Cytarabine;G-CSF;Idarubicin
24 PETHEMA LAM07: Prospective, Multicenter, Uncontrolled Cohort Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML) Completed NCT01041040 Phase 4 gemtuzumab
25 Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia Completed NCT00081926 Phase 4 Gleevec
26 A Phase IV Study of Nilotinib in Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Who Have Suboptimal Molecular Response on Imatinib Completed NCT01043874 Phase 4 Nilotinib
27 An Open-label, Multicenter Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to ENACT (CAMN107A2109) Trial Completed NCT01368523 Phase 4 nilotinib
28 Therapy of AML in Patients Older Than 60 Years: Randomized Comparison of a Double Induction With Daunorubicin and AraC (as Continuous Infusion) With a Double Induction With Mitoxantrone and Intermittent, Medium High Dose AraC Completed NCT00180167 Phase 4 randomization between two established Chemotherapies
29 CRESCENDO (Compliance: Role Emerges for Success in CML: Evaluation aND Optimisation): A Prospective, Multi-center, Phase IV Study to Assess the Compliance in Patients With Philadelphia Chromosome-positive (Ph+) and/or BCR-ABL Positive Chronic Myelogenous Leukaemia (CML) Under Long-term Imatinib Therapy Completed NCT01243489 Phase 4
30 A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Completed NCT01227577 Phase 4 Nilotinib
31 Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Ph+ CML Completed NCT00171899 Phase 4 imatinib mesylate
32 A PHASE 4 SAFETY AND EFFICACY STUDY OF BOSUTINIB (BOSULIF (REGISTERED)) IN PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA PREVIOUSLY TREATED WITH ONE OR MORE TYROSINE KINASE INHIBITORS Completed NCT02228382 Phase 4 Bosutinib
33 An Open-label, Multicenter Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Completed NCT00786812 Phase 4 Nilotinib
34 An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment Completed NCT00980018 Phase 4 Nilotinib
35 Glivec in Pediatric Chronic Myeloid Leukemia (CML) Completed NCT00845221 Phase 4 Imatinib mesylate 100 mg (Glivec)
36 A Phase 4 Study of Nilotinib in Korean Patients With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Chronic Phase Completed NCT03332511 Phase 4 Nilotinib
37 The Feasibility of Safely Managing Patients Receiving Induction With Liposomal Daunorubicin and Cytarabine (CPX-351) for Acute Myeloid Leukemia (AML) in an Outpatient Environment Recruiting NCT03988205 Phase 4 CPX-351
38 Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia: a Prospective Study Comparing Nilotinib Versus Imatinib With Switch to Nilotinib in Absence of Optimal Response. SUSTRENIM Study - GIMEMA CLM1415 Recruiting NCT02602314 Phase 4 Imatinib;Nilotinib
39 Efficacy and Safety of Dasatinib 70 mg as First-Line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Recruiting NCT04155411 Phase 4 Dasatinib
40 A Prospective, Randomized, Controlled Trial of Decitabine Versus Conventional Chemotherapy for Maintenance Therapy of Patients With Acute Myeloid Leukemia With t(8;21) Active, not recruiting NCT03026842 Phase 4 Decitabine;Daunorubicin, Cytarabine;Mitoxantrone, Cytarabine;Aclacinomycin, Cytarabine
41 A Phase IV Single Arm, Multicenter, Open-label Study Assessing Deep Molecular Response in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive CML in Chronic Phase After Two Years of Treatment With Nilotinib 300mg BID Active, not recruiting NCT02546674 Phase 4 Nilotinib
42 A Multi-center, Single Arm Study of Nilotinib in Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Patients With Low Imatinib Trough Plasma Concentrations Terminated NCT01131325 Phase 4 nilotinib
43 PILOT STUDY PHASE II, Multicenter, Non-randomized, TO ASSESS THE EFFICACY AND SAFETY OF LENALIDOMIDE IN INDUCTION AND POST-INDUCTION IN PATIENTS WITH NOVO Acute Myeloid Leukemia (AML) WITH Cytogenetic Abnormality Monosomy 5 Terminated NCT01198054 Phase 4 Lenalidomide
44 Are the Secondary Chromosome Abnormalities Seen in Chronic Myeloid Leukemia (CML) Cells Induced to Ph-Chromosome Negativity by Imatinib a Result of Chromosome Instability or a Side Effect of the Therapy - a Study in GIST (Gastrointestinal Stromal Cell Tumors) Patients Treated With Imatinib. Terminated NCT00461929 Phase 4
45 A Phase IV Study to Evaluate Efficacy and Safety of Imatinib(Glinib®) 600mg/Day Depending on Early Molecular Response in Newly Diagnosed Patients With Chronic Myeloid Leukemia in Chronic Phase Terminated NCT02204722 Phase 4 600mg/day of Imatinib;400mg/day of Imatinib
46 Randomised Comparison of OSHO Induction vs. the German AML Intergroup Standard, Randomised Comparison of AraC/Mtx vs. Flu/AraC/Mtx in Pts Without CR After One Induction Cycle and Randomized Comparison of One vs. Two Consolidation Therapies. Unknown status NCT01414231 Phase 3 Cytarabine
47 Randomised Trial on Allogeneic Haematopoietic Stem Cell Transplantation in Patients Under the Age of 60 Years With Acute Myeloid Leukemia of Intermediate Risk in First Complete Remission and a Matched Sibling or Unrelated Donor (ETAL-1) Unknown status NCT01246752 Phase 3 Consolidation chemotherapy, i.e. High-dose Cytarabine (HiDAC)
48 Autologous Peripheral Blood Stem Cell Transplantation (PSCT) Versus a Second Intensive Consolidation Course After a Common Induction and Consolidation Course in Patients With Bad Prognosis Myelodysplastic Syndromes (MDS) and Acute Myelogenous Leukemia Secondary (SAML) to MDS of More Acute Than 6 Months Duration Unknown status NCT00002926 Phase 3 cytarabine;etoposide;idarubicin
49 RANDOMIZED PHASE III STUDY OF INDUCTION (ICE VS MICE VS DCE) AND INTENSIVE CONSOLIDATION (IDIA VS NOVIA VS DIA) FOLLOWED BY BONE MARROW TRANSPLANTATION IN ACUTE MYELOGENOUS LEUKEMIA: AML 10 PROTOCOL Unknown status NCT00002549 Phase 3 busulfan;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;idarubicin;mesna;mitoxantrone hydrochloride
50 Evaluation of Benefit and Side Effects of Double Umbilical Cord Blood Units Stem Cell Transplantation in Hematologic Malignancies Unknown status NCT01015742 Phase 2, Phase 3 Stem cell Transplantation

Search NIH Clinical Center for Chronic Monocytic Leukemia

Cochrane evidence based reviews: leukemia, myeloid

Genetic Tests for Chronic Monocytic Leukemia

Anatomical Context for Chronic Monocytic Leukemia

MalaCards organs/tissues related to Chronic Monocytic Leukemia:

40
Myeloid, T Cells, Bone, Bone Marrow, Nk Cells, Endothelial, Kidney

Publications for Chronic Monocytic Leukemia

Articles related to Chronic Monocytic Leukemia:

(show top 50) (show all 94)
# Title Authors PMID Year
1
Adoptive immunotherapy with CB following chemotherapy for patients with refractory myeloid malignancy: chimerism and response. 61
33091124 2020
2
Impact of Bone Marrow miR-21 Expression on Acute Myeloid Leukemia T Lymphocyte Fragility and Dysfunction. 61
32911844 2020
3
Epidural myeloid sarcoma as the presenting symptom of chronic myeloid leukemia blast crisis. 61
32458246 2020
4
[Immunohistochemical evaluation of BCL-2 expression in acute myeloid leukemia, myeloid sarcoma, and blastic plasmacytoid dendritic cell neoplasm]. 61
33441515 2020
5
Validated Instruments of Quality of Life (QOL) in Patients With Acute Myeloid Leukemia (AML) and Other Cancers. 61
32792948 2020
6
Complete response of myeloid/lymphoid neoplasms with PDGFRA rearrangement presenting as leukemia/myeloid sarcoma to imatinib monotherapy. 61
31567386 2019
7
Genetic Testing in the Diagnosis and Biology of Myeloid Neoplasms (Excluding Acute Leukemias). 61
31263893 2019
8
Effect of Chronic Hematologic Malignancies on In-Hospital Outcomes of Patients With ST-Segment Elevation Myocardial Infarction. 61
31196560 2019
9
Immunotherapy- (Blinatumomab-) Related Lineage Switch of KMT2A/AFF1 Rearranged B-Lymphoblastic Leukemia into Acute Myeloid Leukemia/Myeloid Sarcoma and Subsequently into B/Myeloid Mixed Phenotype Acute Leukemia. 61
31885955 2019
10
Synchronous Occurrence of Mycosis Fungoides, Diffuse Large B Cell Lymphoma and Acute Myeloid Leukemia. 61
29321428 2018
11
Air pollution from industrial waste gas emissions is associated with cancer incidences in Shanghai, China. 61
29484620 2018
12
Mandible exosomal ssc-mir-133b regulates tooth development in miniature swine via endogenous apoptosis. 61
30210900 2018
13
T-cell transcription factor GATA-3 is an immunophenotypic marker of acute leukemias with T-cell differentiation. 61
28551327 2017
14
Risk for Health Care-Associated Bloodstream Infections in Pediatric Oncology Patients With Various Malignancies. 61
28038498 2017
15
Novel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic). 61
26834952 2016
16
A comprehensive review of occupational and general population cancer risk: 1,3-Butadiene exposure-response modeling for all leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, myeloid neoplasm and lymphoid neoplasm. 61
26070419 2015
17
Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia. 61
26304895 2015
18
Somatic thrombopoietin (THPO) gene mutations in childhood myeloid leukemias. 61
25728710 2015
19
Extensive placental choriovascular infiltration by maturing myeloid cells in down syndrome-associated transient abnormal myelopoiesis. 61
25587735 2015
20
Spectrum of myeloid neoplasms and immune deficiency associated with germline GATA2 mutations. 61
25619630 2015
21
Interpretation of personal genome sequencing data in terms of disease ranks based on mutual information. 61
26045178 2015
22
[Pulmonary function of children with acute leukemia in maintenance phase of chemotherapy]. 61
25510995 2014
23
Proteome changes induced by c-myb silencing in human chronic myeloid leukemia cells suggest molecular mechanisms and putative biomarkers of hematopoietic malignancies. 61
24220303 2014
24
A model approach to calculate cancer prevalence from 5 years survival data for selected cancer sites in India--part II. 61
25081685 2014
25
Partial cytogenetic response with toceranib and prednisone treatment in a young dog with chronic monocytic leukemia. 61
23995854 2013
26
Generation of multi-leukemia antigen-specific T cells to enhance the graft-versus-leukemia effect after allogeneic stem cell transplant. 61
23528871 2013
27
The emerging roles of Notch signaling in leukemia and stem cells. 61
24252593 2013
28
Combination of rapamycin and imatinib in treating refractory chronic myeloid leukemia myeloid blast crisis:a case report(025B3;). 61
23806379 2013
29
Stem cell therapy in treatment of different diseases. 61
22359076 2012
30
Association of HLA antigens and BCR-ABL transcripts in leukemia patients with the Philadelphia chromosome. 61
23049441 2012
31
Current views on the role of Notch signaling and the pathogenesis of human leukemia. 61
22128846 2011
32
Chemotherapeutic treatment for leukemia in a bearded dragon (Pogona vitticeps). 61
22946414 2011
33
BCR-ABL translocation in a dog with chronic monocytic leukemia. 61
21143615 2011
34
Identification of new markers discriminating between myeloid and lymphoid acute leukemia. 61
20670477 2010
35
Possible involvement of RasGRP4 in leukemogenesis. 61
19350351 2009
36
The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. 61
16885047 2006
37
Epigenetic heterochromatin markers distinguish terminally differentiated leukocytes from incompletely differentiated leukemia cells in human blood. 61
16569592 2006
38
Early G2/M checkpoint failure as a molecular mechanism underlying etoposide-induced chromosomal aberrations. 61
16357944 2006
39
Cellular uptake and intracellular levels of the bcl-2 antisense g3139 in cultured cells and treated patients with acute myeloid leukemia. 61
15837754 2005
40
Candidal prosthetic hip infection in a patient with previous candidal septic arthritis. 61
14973873 2004
41
A hybrid form of myeloid/NK-cell acute leukemia and myeloid/NK-cell precursor acute leukemia. 61
12792926 2003
42
Myelomastocytic leukemia: myeloid neoplasm characterized by partial differentiation of mast cell-lineage cells. 61
12032870 2002
43
Acute megakaryocytic leukemia: the Eastern Cooperative Oncology Group experience. 61
11001891 2000
44
Dysregulation of lymphocyte proliferation by chromosomal translocations and sequential genetic changes. 61
10797481 2000
45
Calcium signaling induces acquisition of dendritic cell characteristics in chronic myelogenous leukemia myeloid progenitor cells. 61
10468608 1999
46
Pediatric tumors in north west Pakistan and Afghan refugees. 61
9185211 1997
47
11q23 aberration is an additional chromosomal change in de novo acute leukemia after treatment with etoposide and mitoxantrone. 61
8948668 1996
48
Biological characterization and molecular cloning of murine C-type retroviruses derived from the TSZ complex from mainland China. 61
7571406 1995
49
[Effect of media conditioned with bone marrow fibroblasts on proliferation of leukemic blast cell lines]. 61
7875517 1994
50
[The morphofunctional characteristics of the mononuclear phagocytes in the concentrated venous blood leukocytes of patients with histiocytosis]. 61
7985129 1994

Variations for Chronic Monocytic Leukemia

Expression for Chronic Monocytic Leukemia

Search GEO for disease gene expression data for Chronic Monocytic Leukemia.

Pathways for Chronic Monocytic Leukemia

Pathways related to Chronic Monocytic Leukemia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.55 ITGAD C3

GO Terms for Chronic Monocytic Leukemia

Cellular components related to Chronic Monocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.02 RAMP3 RAMP2 LGALS1 ITGAD C3
2 adrenomedullin receptor complex GO:1903143 8.96 RAMP3 RAMP2

Biological processes related to Chronic Monocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 adenylate cyclase-activating G protein-coupled receptor signaling pathway GO:0007189 9.4 RAMP3 RAMP2
2 keratinocyte differentiation GO:0030216 9.37 EVPL BCR
3 regulation of G protein-coupled receptor signaling pathway GO:0008277 9.32 RAMP3 RAMP2
4 receptor internalization GO:0031623 9.26 RAMP3 RAMP2
5 cellular response to hormone stimulus GO:0032870 9.16 RAMP3 RAMP2
6 amylin receptor signaling pathway GO:0097647 8.96 RAMP3 RAMP2
7 adrenomedullin receptor signaling pathway GO:1990410 8.62 RAMP3 RAMP2

Molecular functions related to Chronic Monocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 coreceptor activity GO:0015026 9.16 RAMP3 RAMP2
2 amylin receptor activity GO:0097643 8.96 RAMP3 RAMP2
3 adrenomedullin receptor activity GO:0001605 8.62 RAMP3 RAMP2

Sources for Chronic Monocytic Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....